Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?

BACKGROUND: Pituitary carcinomas are rare but aggressive and require maximally coordinated multimodal therapies. For refractory tumors, unresponsive to temozolomide (TMZ), therapeutic options are limited. Immune checkpoint inhibitors (ICI) may be considered for treatment as illustrated in the presen...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Eur J Endocrinol
Main Authors: Sol, Bastiaan, de Filette, Jeroen M K, Awada, Gil, Raeymaeckers, Steven, Aspeslagh, Sandrine, Andreescu, C E, Neyns, Bart, Velkeniers, Brigitte
Formato: Artigo
Idioma:Inglês
Publicado: Bioscientifica Ltd 2020
Assuntos:
Brief Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7707801/
https://ncbi.nlm.nih.gov/pubmed/33112279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-20-0151
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares